eFFECTOR Therapeutics (DB:LWK) - Hisse Senedi Fiyatı, Haberler ve Analizler

LWK Stoklara Genel Bakış

A biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Daha fazla detay

LWK temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Risk Analizi

Hisse senetleri oldukça likit değildir

Anlamlı bir piyasa değeri yok ( €203K )

Geliri 1 milyon ABD dolarından az ( $0 )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

+ 1 daha fazla risk

eFFECTOR Therapeutics, Inc. Rakipler

bioXXmed

XTRA:T5O

€1.4m

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€17.4m

4SC

DB:VSC

€50.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti eFFECTOR Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.08
52 Haftanın En Yüksek Seviyesi	US$15.88
52 Haftanın En Düşük Seviyesi	US$1.06
Beta	0.62
11 Aylık Değişim	0%
3 Aylık Değişim	0.47%
1 Yıllık Değişim	-90.89%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-99.71%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	LWK	DE Biotechs	DE Pazar
7D	0%	-1.1%	1.1%
1Y	-90.9%	-18.8%	7.2%

Getiri vs. Endüstri: LWK geçen yıl % -18.8 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: LWK geçen yıl % 7.2 oranında getiri sağlayan German Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is LWK's price volatile compared to industry and market?
LWK volatility
LWK Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: LWK son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: LWK 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2012	14	Craig Jalbert	effector.com

eFFECTOR Therapeutics, Inc. Temel Bilgiler Özeti

eFFECTOR Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
LWK temel i̇stati̇sti̇kler
Piyasa değeri	€182.26k
Kazançlar(TTM)	-€31.02m
Gelir(TTM)	n/a

0.0x

P/S Oranı

0.0x

F/K Oranı

LWK aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
LWK gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$21.62m
Brüt Kâr	-US$21.62m
Diğer Giderler	US$13.02m
Kazançlar	-US$34.63m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-7.36
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	2,420.3%

LWK uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

LWK Stoklara Genel Bakış

Risk Analizi

eFFECTOR Therapeutics, Inc. Rakipler

XTRA:T5O

€1.4m

XTRA:CNW

€6.5m

XTRA:MDG1

€17.4m

DB:VSC

€50.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

eFFECTOR Therapeutics Files Form 15

eFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index

eFFECTOR Therapeutics Provides Non-Compliance Update

eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term

eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term

eFFECTOR Therapeutics, Inc. Receives Written Notice from Nasdaq Regarding Minimum Value of Listed Securities

Recent updates

eFFECTOR Therapeutics Files Form 15

eFFECTOR Therapeutics, Inc.(OTCPK:EFTR) dropped from NASDAQ Composite Index

eFFECTOR Therapeutics Provides Non-Compliance Update

eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term

eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term

eFFECTOR Therapeutics, Inc. Receives Written Notice from Nasdaq Regarding Minimum Value of Listed Securities

New major risk - Revenue and earnings growth

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

New major risk - Market cap size

eFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.000003 million.

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.000003 million.

eFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients

eFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer

New major risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.23 loss in 3Q 2022)

Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia (Aml)

eFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq Stock Market Regarding Non-Compliance with Nasdaq's Minimum Bid Price Requirement

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.733186 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 22, 2023

High number of new directors

High number of new directors

eFFECTOR Therapeutics, Inc. Provides Positive Clinical Data Update for Zotatifin and General Corporate Update

High number of new directors

High number of new directors

Effector Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1B Clinical Trial of Zotatifin for the Treatment of Covid-19

High number of new directors

Effector Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

eFFECTOR Therapeutics, Inc. Doses First Patient in Second Cohort of Phase 1B Clinical Trial of Zotatifin for the Treatment of Covid-19

eFFECTOR Therapeutics Receives A Letter from the Nasdaq Stock Market Staff

eFFECTOR Therapeutics Appoints Douglas Warner as Chief Medical Officer

eFFECTOR Therapeutics, Inc. Announces Executive Changes

Investor sentiment deteriorated over the past week

eFFECTOR Therapeutics, Inc. Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity

Investor sentiment improved over the past week

eFFECTOR Therapeutics, Inc. Announces Interim Data from Its Ongoing Phase 1/2 Clinical Trial of Zotatifin in Solid Tumors

Investor sentiment deteriorated over the past week

High number of new directors

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

eFFECTOR Therapeutics, Inc. Announces Transition in Clinical Leadership

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

eFFECTOR Therapeutics, Inc. Announces Directorate Changes

eFFECTOR Therapeutics, Inc. Provides Pipeline and Business Updates

High number of new directors

Independent Director recently sold €420k worth of stock

Independent Director recently sold €366k worth of stock

eFFECTOR Therapeutics, Inc. Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

Independent Director recently sold €362k worth of stock

Independent Director recently sold €196k worth of stock

Independent Director recently sold €801k worth of stock

Third quarter 2021 earnings released: EPS US$0.53

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında